- THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
-
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
- -
-
Paragraph 0423
(2020/03/09)
-
- THYROID HORMONE RECEPTOR AGONISTS
-
Provided herein are novel thyroid hormone receptor (TR) agonists, e. g., having Formula I, II, or III. Also provided are methods of preparing the novel TR agonists and method of using the novel TR agonists for treating diseases or disorder modulated by TR agonists, such as NAFLD, NASH, diabetes, hyperlipidemia and/or hypercholesterolemia.
- -
-
Paragraph 246
(2020/05/19)
-
- PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS
-
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.
- -
-
Page/Page column 126-127
(2008/06/13)
-
- Anticoccidial derivatives of 6-azauracil. 3. Synthesis, high activity, and short plasma half-life of 1-phenyl-6-azauracils containing sulfonamide substituents
-
A series of 1-phenyl-6-azauracils containing sulfonamide substituents was prepared. In contrast to previous 1-phenyl-6-azauracils, some of these sulfonamides combine high activity against Eimeria tenella infections in chickens with a very rapid rate of clearance from plasma. Most active was 1-[3'-chloro-5'-methyl-4'-(morpholinyl-sulfonyl)phenyl]-6-azauracil, with a minimum effective concentration in feed of about 10 ppm.
- Miller,Mylari,Howes Jr.,Figdor,Lynch,Lynch,Koch
-
p. 1083 - 1087
(2007/10/02)
-